OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
Aptamers 2019
03-04 April 2019, Oxford
Submit a manuscript

By

admin
RESEARCH REPORT ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 18 May 2018 Full Text Access Alexander S Chiu1,*, Vinoth Sankarapani1, Rafal Drabek1, George W Jackson1, Robert H Batchelor1 and Yoon-Seong Kim2 1Base Pair Biotechnologies, 8619 Broadway St, Suite 100, Pearland, Texas, 77584, USA 2Nexmos Co Ltd, 2207 U-Tower, 767 Sinsu-Ro, Sooji-Gu, Yongin-Si, Gyeonggi-Do,...
Read More
REVIEW ARTICLE ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 27 April 2018 Full Text Access  Joanna Macdonald1, Giovanni Mandarano1, Rakesh Naduvile Veedu2,3, and Sarah Shigdar1,4,* 1School of Medicine Deakin University, Geelong, VIC, Australia- 3216 2Centre for Comparative Genomics, Murdoch University, Perth, WA, Australia-6150 3Perron Institute for Neurological and Translational Science, Perth, WA, Australia...
Read More
MEETING REVIEW ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 12 Feb 2018 Full Text Access  Justin Henri1, Maureen McKeague2, Philip E Johnson3, Beatrix Suess4, Yoshikazu Nakamura5,6, Marit Nilsen-Hamilton7,8, Fernando Pastor9, Ulrich Hahn10, David Bunka11, Sarah Shigdar1,12 1School of Medicine Deakin University, Geelong, Victoria 3128, Australia 2Department of Health Sciences and Technology, ETH Zürich, Schmelzbergstrasse...
Read More
Aptamer Solutions Ltd: Continued success and growth has enabled Aptamer Group to restructure its Scientific Operations team. Increasing interest in the development of aptamers against small molecule targets has led to the formation of a dedicated scientific team. This is in addition to the existing team focused on aptamer generation against larger targets (proteins, viruses,...
Read More
REVIEW ARTICLE ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 04 Feb 2018 Full Text Access  Amal Moh Awwad1 and Maureen McKeague2,* 1Institute of Biochemistry, Carleton University, 1125 Colonel By Drive, Ottawa, ON, Canada 2Department of Health Sciences and Technology, ETH Zürich, Schmelzbergstrasse 9, 8092 Zürich, Switzerland *Correspondence to: Maureen McKeague, E-mail: maureen.mckeague@hest.ethz.ch Received:...
Read More
Pure Biologics is a biopharmaceutical company. We are conducting in-house research projects for the development of new biopharmaceutical drugs, diagnostics tests and therapeutical medical devices. Our company has a unique technological know-how with proprietary platforms for selection of antibody fragments and chemically modified aptamers. We are leveraging these technologies to employ biological binding entities for drug...
Read More
RESEARCH ARTICLE ISSN: 2514-3247Aptamers (2017), Vol 1, 19-27 Published online: 15 December 2017 Full Text Access Victoria Calzada1*, Jessica Báez 1, Estefanía Sicco1, Jimena Margenat1, Marcelo Fernández2, María Moreno3, Manuel Ibarra4, Thomas Quinn5, Juan Pablo Gambini6, Pablo Cabral1 and Hugo Cerecetto1 1Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Uruguay 2Laboratorio de...
Read More
Centauri Therapeutics Ltd is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The company has established a core R&D facility at Discovery Park in Sandwich, Kent, with an experienced team of industry scientists focused on discovery, optimisation and development of novel Alphamers targeting acute hospital acquired infections....
Read More
1 2 3 4 18

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases